Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.

ClinicoEconomics and outcomes research : CEOR

Knight T, Schaefer C, Krasa H, Oberdhan D, Chapman A, Perrone RD.
PMID: 25759590
Clinicoecon Outcomes Res. 2015 Feb 20;7:123-32. doi: 10.2147/CEOR.S75523. eCollection 2015.

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) results in kidney cyst development and enlargement, resulting in chronic kidney disease (CKD) leading to renal failure. This study sought to determine if ADPKD patients in the early stages of CKD contribute...

Cite
Knight T, Schaefer C, Krasa H, et al. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. Clinicoecon Outcomes Res. 2015;7:123-32doi: 10.2147/CEOR.S75523.
Knight, T., Schaefer, C., Krasa, H., Oberdhan, D., Chapman, A., & Perrone, R. D. (2015). Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. ClinicoEconomics and outcomes research : CEOR, 7123-32. https://doi.org/10.2147/CEOR.S75523
Knight, Tyler, et al. "Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data." ClinicoEconomics and outcomes research : CEOR vol. 7 (2015): 123-32. doi: https://doi.org/10.2147/CEOR.S75523
Knight T, Schaefer C, Krasa H, Oberdhan D, Chapman A, Perrone RD. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. Clinicoecon Outcomes Res. 2015 Feb 20;7:123-32. doi: 10.2147/CEOR.S75523. eCollection 2015. PMID: 25759590; PMCID: PMC4345925.
Copy Download .nbib Format: NLM
Can BMI-1 be a biomarker of poor prognosis?.

Epigenomics

Itahana K, Dimri GP.
PMID: 22122046
Epigenomics. 2010 Oct;2(5):609-10. doi: 10.2217/epi.10.52.

No abstract available.

Cite
Itahana K, Dimri GP. Can BMI-1 be a biomarker of poor prognosis?. Epigenomics. 2010;2(5):609-10doi: 10.2217/epi.10.52.
Itahana, K., & Dimri, G. P. (2010). Can BMI-1 be a biomarker of poor prognosis?. Epigenomics, 2(5), 609-10. https://doi.org/10.2217/epi.10.52
Itahana, Koji, and Dimri, Goberdhan P. "Can BMI-1 be a biomarker of poor prognosis?." Epigenomics vol. 2,5 (2010): 609-10. doi: https://doi.org/10.2217/epi.10.52
Itahana K, Dimri GP. Can BMI-1 be a biomarker of poor prognosis?. Epigenomics. 2010 Oct;2(5):609-10. doi: 10.2217/epi.10.52. PMID: 22122046.
Copy Download .nbib Format: NLM
Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding.

Pulmonary circulation

Kumar B, Puri GD, Manoj R, Gupta K, Shyam KS.
PMID: 22034598
Pulm Circ. 2011 Jan-Mar;1(1):115-8. doi: 10.4103/2045-8932.78099.

Although mild increase in pulmonary vascular resistance following intracardiac repair of tetralogy of Fallot is often seen in the early postoperative period, it usually subsides without any sequel. Persistent severe pulmonary artery hypertension after total correction is rare. We...

Cite
Kumar B, Puri GD, Manoj R, et al. Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding. Pulm Circ. 2011;1(1):115-8doi: 10.4103/2045-8932.78099.
Kumar, B., Puri, G. D., Manoj, R., Gupta, K., & Shyam, K. S. (2011). Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding. Pulmonary circulation, 1(1), 115-8. https://doi.org/10.4103/2045-8932.78099
Kumar, Bhupesh, et al. "Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding." Pulmonary circulation vol. 1,1 (2011): 115-8. doi: https://doi.org/10.4103/2045-8932.78099
Kumar B, Puri GD, Manoj R, Gupta K, Shyam KS. Severe pulmonary artery hypertension following intracardiac repair of tetralogy of Fallot: An unusual finding. Pulm Circ. 2011 Jan-Mar;1(1):115-8. doi: 10.4103/2045-8932.78099. PMID: 22034598; PMCID: PMC3198627.
Copy Download .nbib Format: NLM
Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder.

Neuropsychiatric disease and treatment

Markowitz JT, Oberdhan D, Ciesluk A, Rams A, Wigal SB.
PMID: 32669845
Neuropsychiatr Dis Treat. 2020 Jul 01;16:1619-1643. doi: 10.2147/NDT.S248685. eCollection 2020.

PURPOSE: Various clinical outcome assessments (COAs) are used in clinical research to assess and monitor treatment efficacy in pediatric attention-deficit/hyperactivity disorder (ADHD) trials. It is unclear whether the concepts assessed are those that are important to patients and their...

Cite
Markowitz JT, Oberdhan D, Ciesluk A, et al. Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder. Neuropsychiatr Dis Treat. 2020;16:1619-1643doi: 10.2147/NDT.S248685.
Markowitz, J. T., Oberdhan, D., Ciesluk, A., Rams, A., & Wigal, S. B. (2020). Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder. Neuropsychiatric disease and treatment, 161619-1643. https://doi.org/10.2147/NDT.S248685
Markowitz, Jessica T, et al. "Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder." Neuropsychiatric disease and treatment vol. 16 (2020): 1619-1643. doi: https://doi.org/10.2147/NDT.S248685
Markowitz JT, Oberdhan D, Ciesluk A, Rams A, Wigal SB. Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder. Neuropsychiatr Dis Treat. 2020 Jul 01;16:1619-1643. doi: 10.2147/NDT.S248685. eCollection 2020. PMID: 32669845; PMCID: PMC7335865.
Copy Download .nbib Format: NLM
GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.

Nature communications

Dar GH, Mendes CC, Kuan WL, Speciale AA, Conceição M, Görgens A, Uliyakina I, Lobo MJ, Lim WF, El Andaloussi S, Mäger I, Roberts TC, Barker RA, Goberdhan DCI, Wilson C, Wood MJA.
PMID: 34795295
Nat Commun. 2021 Nov 18;12(1):6666. doi: 10.1038/s41467-021-27056-3.

Extracellular vesicles (EVs) are biological nanoparticles with important roles in intercellular communication, and potential as drug delivery vehicles. Here we demonstrate a role for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in EV assembly and secretion. We observe high levels...

Cite
Dar GH, Mendes CC, Kuan WL, et al. GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nat Commun. 2021;12(1):6666doi: 10.1038/s41467-021-27056-3.
Dar, G. H., Mendes, C. C., Kuan, W. L., Speciale, A. A., Conceição, M., Görgens, A., Uliyakina, I., Lobo, M. J., Lim, W. F., El Andaloussi, S., Mäger, I., Roberts, T. C., Barker, R. A., Goberdhan, D. C. I., Wilson, C., & Wood, M. J. A. (2021). GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nature communications, 12(1), 6666. https://doi.org/10.1038/s41467-021-27056-3
Dar, Ghulam Hassan, et al. "GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain." Nature communications vol. 12,1 (2021): 6666. doi: https://doi.org/10.1038/s41467-021-27056-3
Dar GH, Mendes CC, Kuan WL, Speciale AA, Conceição M, Görgens A, Uliyakina I, Lobo MJ, Lim WF, El Andaloussi S, Mäger I, Roberts TC, Barker RA, Goberdhan DCI, Wilson C, Wood MJA. GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nat Commun. 2021 Nov 18;12(1):6666. doi: 10.1038/s41467-021-27056-3. PMID: 34795295; PMCID: PMC8602309.
Copy Download .nbib Format: NLM
Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study.

International journal of nephrology and renovascular disease

Sanon Aigbogun M, Oberdhan D, Doane MJ, Rooney J, Inyart BC, Pao CS, Denny AH.
PMID: 33880055
Int J Nephrol Renovasc Dis. 2021 Apr 13;14:105-115. doi: 10.2147/IJNRD.S297491. eCollection 2021.

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a rare inherited kidney disorder with considerable symptom burden and negative effects even in early-stage disease. Patients' reporting of ADPKD symptom burden may differ from physicians' impressions. In this quantitative, cross-section...

Cite
Sanon Aigbogun M, Oberdhan D, Doane MJ, et al. Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study. Int J Nephrol Renovasc Dis. 2021;14:105-115doi: 10.2147/IJNRD.S297491.
Sanon Aigbogun, M., Oberdhan, D., Doane, M. J., Rooney, J., Inyart, B. C., Pao, C. S., & Denny, A. H. (2021). Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study. International journal of nephrology and renovascular disease, 14105-115. https://doi.org/10.2147/IJNRD.S297491
Sanon Aigbogun, Myrlene, et al. "Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study." International journal of nephrology and renovascular disease vol. 14 (2021): 105-115. doi: https://doi.org/10.2147/IJNRD.S297491
Sanon Aigbogun M, Oberdhan D, Doane MJ, Rooney J, Inyart BC, Pao CS, Denny AH. Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study. Int J Nephrol Renovasc Dis. 2021 Apr 13;14:105-115. doi: 10.2147/IJNRD.S297491. eCollection 2021. PMID: 33880055; PMCID: PMC8053527.
Copy Download .nbib Format: NLM
GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.

Nature communications

Dar GH, Mendes CC, Kuan WL, Speciale AA, Conceição M, Görgens A, Uliyakina I, Lobo MJ, Lim WF, El Andaloussi S, Mäger I, Roberts TC, Barker RA, Goberdhan DCI, Wilson C, Wood MJA.
PMID: 34795295
Nat Commun. 2021 Nov 18;12(1):6666. doi: 10.1038/s41467-021-27056-3.

Extracellular vesicles (EVs) are biological nanoparticles with important roles in intercellular communication, and potential as drug delivery vehicles. Here we demonstrate a role for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in EV assembly and secretion. We observe high levels...

Cite
Dar GH, Mendes CC, Kuan WL, et al. GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nat Commun. 2021;12(1):6666doi: 10.1038/s41467-021-27056-3.
Dar, G. H., Mendes, C. C., Kuan, W. L., Speciale, A. A., Conceição, M., Görgens, A., Uliyakina, I., Lobo, M. J., Lim, W. F., El Andaloussi, S., Mäger, I., Roberts, T. C., Barker, R. A., Goberdhan, D. C. I., Wilson, C., & Wood, M. J. A. (2021). GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nature communications, 12(1), 6666. https://doi.org/10.1038/s41467-021-27056-3
Dar, Ghulam Hassan, et al. "GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain." Nature communications vol. 12,1 (2021): 6666. doi: https://doi.org/10.1038/s41467-021-27056-3
Dar GH, Mendes CC, Kuan WL, Speciale AA, Conceição M, Görgens A, Uliyakina I, Lobo MJ, Lim WF, El Andaloussi S, Mäger I, Roberts TC, Barker RA, Goberdhan DCI, Wilson C, Wood MJA. GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. Nat Commun. 2021 Nov 18;12(1):6666. doi: 10.1038/s41467-021-27056-3. PMID: 34795295; PMCID: PMC8602309.
Copy Download .nbib Format: NLM
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.

Kidney international reports

Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE.
PMID: 32518861
Kidney Int Rep. 2020 Mar 17;5(6):790-800. doi: 10.1016/j.ekir.2020.03.013. eCollection 2020 Jun.

INTRODUCTION: Tolvaptan, for treatment of autosomal dominant polycystic kidney disease (ADPKD), is provided as immediate-release (IR) tablets administered twice daily in split-dose regimens to suppress urine osmolality to 

Cite
Perrone RD, Chapman AB, Oberdhan D, et al. A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney Int Rep. 2020;5(6):790-800doi: 10.1016/j.ekir.2020.03.013.
Perrone, R. D., Chapman, A. B., Oberdhan, D., Czerwiec, F. S., Sergeyeva, O., Ouyang, J., & Shoaf, S. E. (2020). A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney international reports, 5(6), 790-800. https://doi.org/10.1016/j.ekir.2020.03.013
Perrone, Ronald D, et al. "A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD." Kidney international reports vol. 5,6 (2020): 790-800. doi: https://doi.org/10.1016/j.ekir.2020.03.013
Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE. A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney Int Rep. 2020 Mar 17;5(6):790-800. doi: 10.1016/j.ekir.2020.03.013. eCollection 2020 Jun. PMID: 32518861; PMCID: PMC7271942.
Copy Download .nbib Format: NLM
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.

Kidney international reports

Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE.
PMID: 32518862
Kidney Int Rep. 2020 Apr 27;5(6):801-812. doi: 10.1016/j.ekir.2020.03.011. eCollection 2020 Jun.

INTRODUCTION: Tolvaptan, a treatment for autosomal dominant polycystic kidney disease (ADPKD), inhibits vasopressin V2 receptor signaling, which causes aquaretic adverse events (AAEs). The short-term efficacy and tolerability of a once-daily, modified-release (MR) formulation was assessed relative to the twice-daily,...

Cite
Perrone RD, Chapman AB, Oberdhan D, et al. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney Int Rep. 2020;5(6):801-812doi: 10.1016/j.ekir.2020.03.011.
Perrone, R. D., Chapman, A. B., Oberdhan, D., Czerwiec, F. S., Sergeyeva, O., Ouyang, J., & Shoaf, S. E. (2020). The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney international reports, 5(6), 801-812. https://doi.org/10.1016/j.ekir.2020.03.011
Perrone, Ronald D, et al. "The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations." Kidney international reports vol. 5,6 (2020): 801-812. doi: https://doi.org/10.1016/j.ekir.2020.03.011
Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney Int Rep. 2020 Apr 27;5(6):801-812. doi: 10.1016/j.ekir.2020.03.011. eCollection 2020 Jun. PMID: 32518862; PMCID: PMC7271939.
Copy Download .nbib Format: NLM
Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles.

Journal of extracellular vesicles

Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L.
PMID: 34953156
J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182.

The minimal information for studies of extracellular vesicles (EVs, MISEV) is a field-consensus rigour initiative of the International Society for Extracellular Vesicles (ISEV). The last update to MISEV, MISEV2018, was informed by input from more than 400 scientists and...

Cite
Witwer KW, Goberdhan DC, O'Driscoll L, et al. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182doi: 10.1002/jev2.12182.
Witwer, K. W., Goberdhan, D. C., O'Driscoll, L., Théry, C., Welsh, J. A., Blenkiron, C., Buzás, E. I., Di Vizio, D., Erdbrügger, U., Falcón-Pérez, J. M., Fu, Q. L., Hill, A. F., Lenassi, M., Lötvall, J., Nieuwland, R., Ochiya, T., Rome, S., Sahoo, S., & Zheng, L. (2021). Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. Journal of extracellular vesicles, 10(14), e12182. https://doi.org/10.1002/jev2.12182
Witwer, Kenneth W, et al. "Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles." Journal of extracellular vesicles vol. 10,14 (2021): e12182. doi: https://doi.org/10.1002/jev2.12182
Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182. PMID: 34953156.
Copy Download .nbib Format: NLM
Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles.

Journal of extracellular vesicles

Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L.
PMID: 34953156
J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182.

The minimal information for studies of extracellular vesicles (EVs, MISEV) is a field-consensus rigour initiative of the International Society for Extracellular Vesicles (ISEV). The last update to MISEV, MISEV2018, was informed by input from more than 400 scientists and...

Cite
Witwer KW, Goberdhan DC, O'Driscoll L, et al. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182doi: 10.1002/jev2.12182.
Witwer, K. W., Goberdhan, D. C., O'Driscoll, L., Théry, C., Welsh, J. A., Blenkiron, C., Buzás, E. I., Di Vizio, D., Erdbrügger, U., Falcón-Pérez, J. M., Fu, Q. L., Hill, A. F., Lenassi, M., Lötvall, J., Nieuwland, R., Ochiya, T., Rome, S., Sahoo, S., & Zheng, L. (2021). Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. Journal of extracellular vesicles, 10(14), e12182. https://doi.org/10.1002/jev2.12182
Witwer, Kenneth W, et al. "Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles." Journal of extracellular vesicles vol. 10,14 (2021): e12182. doi: https://doi.org/10.1002/jev2.12182
Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182. PMID: 34953156.
Copy Download .nbib Format: NLM
Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles.

Journal of extracellular vesicles

Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L.
PMID: 34953156
J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182.

The minimal information for studies of extracellular vesicles (EVs, MISEV) is a field-consensus rigour initiative of the International Society for Extracellular Vesicles (ISEV). The last update to MISEV, MISEV2018, was informed by input from more than 400 scientists and...

Cite
Witwer KW, Goberdhan DC, O'Driscoll L, et al. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182doi: 10.1002/jev2.12182.
Witwer, K. W., Goberdhan, D. C., O'Driscoll, L., Théry, C., Welsh, J. A., Blenkiron, C., Buzás, E. I., Di Vizio, D., Erdbrügger, U., Falcón-Pérez, J. M., Fu, Q. L., Hill, A. F., Lenassi, M., Lötvall, J., Nieuwland, R., Ochiya, T., Rome, S., Sahoo, S., & Zheng, L. (2021). Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. Journal of extracellular vesicles, 10(14), e12182. https://doi.org/10.1002/jev2.12182
Witwer, Kenneth W, et al. "Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles." Journal of extracellular vesicles vol. 10,14 (2021): e12182. doi: https://doi.org/10.1002/jev2.12182
Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021 Dec;10(14):e12182. doi: 10.1002/jev2.12182. PMID: 34953156; PMCID: PMC8710080.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries